Sulzer hip implant settlement progress marred by Texas verdict
This article was originally published in Clinica
Executive Summary
Swiss company Sulzer Medica has hit out at a $15.1 million verdict against its Sulzer Orthopedics division in favour of three women who underwent revision surgery after receiving a faulty hip implant made by the company. It argues that its own proposed settlement plan represents the best solution for all patients. The company also said the verdict was "totally out of line for this case and it will not stand on appeal".
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.